Clinical dose-escalation study of auto-gammadelta T cell therapy for multiple myeloma to investigate its safety and efficacy

Clinical dose-escalation study of auto-gammadelta T cell therapy for multiple myeloma to investigate its safety and efficacy - Clinical study of gammadelta T cell therapy for multiple myeloma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000343

Enrollment

Registered

2006-03-01

Start date

2005-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma

Interventions

Gammadelta T cell is to be administrated intravenously four times on a biweekly-basis.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Multiple myeloma patients who have received a series of induction chemotherapy 20 years or more Performance status 0-1 No serious abnormality in bone marrow, liver and/or renal functions

Exclusion criteria

Exclusion criteria: Patients who have : uncontrolled infections; active autoimmune diseases; serious cardiac disease; other cancers, and who have received continuous systemic steroids

Design outcomes

Primary

Measure	Time frame
Safety : Adverse events	—

Secondary

Measure	Time frame
Efficacy : Improvement and maintenance of tumor-related immuno/biochemistrical parameters	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026